Related Experiment Video
Updated: May 8, 2026
06:09
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
22.7K
Structural analysis of the full-length human LRRK2.
Alexander Myasnikov1, Hanwen Zhu2, Patricia Hixson2
1Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Cryo-EM and Tomography Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Cell
|June 9, 2021
Summary
Structural insights into leucine-rich repeat kinase 2 (LRRK2) reveal its inactive conformation and dimerization. This provides a framework for developing Parkinson
Area of Science:
- Biochemistry
- Structural Biology
- Neuroscience
Background:
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are key drivers of Parkinson's disease (PD) pathogenesis.
- The precise molecular mechanisms underlying LRRK2's cellular functions and role in PD remain unclear.
- LRRK2 is involved in cellular processes at organelle membranes and forms pathogenic filaments.
Purpose of the Study:
- To elucidate the high-resolution structure of full-length human LRRK2.
- To understand the structural basis of LRRK2's physiological and pathological roles.
- To provide a structural template for developing Parkinson's disease therapeutics.
Main Methods:
- Determined high-resolution structures of full-length human LRRK2.
- Analyzed the kinase domain conformation.
- Determined the structure of COR-mediated LRRK2 dimers.
Main Results:
- Revealed the overall architecture of LRRK2 and key interdomain scaffolding elements.
- Captured the LRRK2 kinase domain in an inactive conformation, also adopted by the G2019S mutation.
- Identified that mutations at the COR-mediated dimer interface disrupt pathogenic filament formation in cells.
Conclusions:
- The study provides mechanistic insights into LRRK2's function and role in Parkinson's disease.
- The determined structures offer a framework for structure-guided design of conformation-specific inhibitors.
- Structural understanding of LRRK2 facilitates the development of targeted Parkinson's disease therapies.
